Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RECTIV vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (c GMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
FDA-approved: Treatment of moderate to severe pain associated with chronic anal fissures
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Terminal elimination half-life is approximately 2-4 hours in healthy adults. In patients with severe hepatic impairment, half-life may be prolonged up to 8-10 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Primarily hepatic metabolism via glutathione-organic nitrate reductase, with subsequent denitration and conjugation. Metabolites include inorganic nitrate and 1,2-glyceryl dinitrate. Also undergoes hydrolysis by esterases.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Primarily renal; approximately 60-70% of the parent drug and metabolites excreted in urine within 24 hours. Fecal elimination accounts for ~20-30% via biliary secretion. Less than 1% unchanged drug recovered in feces.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Approximately 60% bound to plasma proteins, primarily albumin. Binding is reversible and concentration-dependent.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
Volume of distribution is approximately 2-4 L/kg, indicating extensive tissue distribution. Clinical meaning: high Vd suggests significant uptake into vascular smooth muscle and other tissues.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual: approximately 40-50% due to first-pass metabolism. Oral: <10% due to extensive hepatic first-pass effect. Topical (RECTIV): systemic bioavailability is negligible (<1%) when applied as directed to the anal mucosa.
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dosage adjustment required for renal impairment. Use with caution in severe impairment due to potential for volume depletion.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 1 gram (0.5 mg) once daily. Child-Pugh C: contraindicated.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Safety and efficacy not established in pediatric patients under 18 years.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Use with caution; start at lowest effective dose (1 gram) and monitor for hypotension. Consider decreased renal/hepatic function.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
No FDA boxed warning.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension and syncope: Use with caution in patients with hypotension, hypovolemia, or those taking antihypertensives.,Severe anemia or conditions where vasodilation is detrimental.,Concomitant use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) is contraindicated due to risk of severe hypotension.,May cause headaches and local burning or itching at application site.
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Concomitant use of PDE-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil),History of hypersensitivity to nitroglycerin or any component of the formulation,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Circulatory failure (shock) or severe hypotension
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
No specific food restrictions. Avoid alcohol as it may worsen hypotension and headache. Grapefruit juice may increase nitroglycerin levels; avoid concurrent consumption.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 50 times the recommended human dose). No well-controlled studies in pregnant women; use only if clearly needed. Fetal risk cannot be ruled out.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Not recommended during breastfeeding. Drug is administered topically for hemorrhoids; systemic absorption is minimal, but no data on excretion in human milk. M/P ratio not determined.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No dose adjustment required; pharmacokinetics not studied in pregnancy. Use the same dose as in non-pregnant patients, but with caution due to lack of safety data.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
RECTIV (nitroglycerin) 0.4% ointment is indicated for chronic anal fissure pain. Apply a 1-inch strip intra-anally every 12 hours for up to 8 weeks. May cause headache; monitor blood pressure. Contraindicated with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Avoid in patients with hypotension (SBP <90 mm Hg) or hypovolemia. Do not use with strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat).
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Apply 1-inch strip of ointment inside the anus every 12 hours using the applicator.,Wash hands before and after application.,Do not use more than 8 weeks unless directed by your doctor.,Avoid sexual activity during treatment as partner may absorb medication.,Do not take erectile dysfunction drugs (Viagra, Cialis, Levitra) while using this medication.,Seek medical help if you experience severe headache, dizziness, or fainting.,Store at room temperature away from heat and direct light.,Do not use if you have low blood pressure or are dehydrated.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RECTIV vs MONOKET, answered by our medical review team.
RECTIV is a Nitrate Vasodilator that works by RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (c GMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RECTIV and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RECTIV is: 1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RECTIV and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RECTIV is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 50 times the recommended human dose). No well-controlled studies in. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.